Data

The Moo'D Study: A randomised controlled trial of A2 vs conventional dairy products in women with low mood.

Deakin University

Dataset description

This trial evaluated the comparative effects of consumption of dairy products containing A2 beta-casein versus conventional dairy (i.e. containing both A1 and A2 beta-casein) on symptoms of psychological distress in women with low mood. ‘The Moo’D Study’ is a 16-week, superiority, 1:1 parallel group, triple-blinded, randomised controlled trial. Ninety women with low mood (Patient Health Questionnaire score ≥ 5) will be randomised to consume either A2 beta-casein only or conventional dairy products. The primary outcome, symptoms of psychological distress, were measured by the 21-item Depression, Anxiety and Stress Scale. Secondary outcomes include symptoms of depression, anxiety and stress, severity of low mood, cognition, gut microbiota composition, gut symptomatology, markers of immune function, gut inflammation, systemic metabolites, endothelial integrity and oxidative stress, body composition, perceived wellbeing, sleep, quality of life, resource use and cost-effectiveness.
Click to explore relationships graph

Source Study

Trial acronym

The Moo'D Study

Trial ID

ACTRN12618002023235

Purpose

Treatment

Phase

Not Applicable

Funding

University,Deakin University

Scientific enquiries

Prof Felice N Jacka

Brief Summary

The aim of this present randomised controlled trial is to assess the possible effects of 16-week consumption of A2 dairy products, versus conventional dairy products, on symptoms of psychological distress in 90 women with low mood. Secondary aims of this study are to assess possible effects from consumption of these two dairy products on symptoms of depression, anxiety and stress; gut symptoms; gut microbiota; body composition; cognition; well-being; health-related quality of life; and biomarker ....
Read more

Key Inclusion Criteria

Female participants with low mood as determined by a PHQ-8 score of 5 or higher at baseline. Current conventional milk consumption of at least 250ml/day. Willingness to commit to consuming only dairy products provided by the study. Available for intervention duration. Able to understand study materials and directions, in English. Must have access to internet and a computer/smartphone/tablet. Be willing to comply with all requirements and procedures of the study. Agree not to enrol in another int ....
Read more

Key Exclusion Criteria

Current consumer of A2 dairy products. Cow’s milk (dairy) allergy (established diagnosis). Lactose intolerance (established diagnosis). Pregnant, planning to become pregnant, or lactating. History of dementia and/or stroke. Diagnosed with or commenced new treatment for, anxiety and/or depression, within 1 month prior to baseline. Gastrointestinal (GI) diseases or past major GI surgery likely to interfere with study outcomes (e.g. ulcerative colitis, crohn's disease, faecal impaction, coeliac dis ....
Read more

Can healthy volunteers participate?

No

 

Population

Sample Size    74

Min. age    18 Years

Max. age    75 Years

Sex    Females

Condition category    Psychological distress

Condition code    Mental Health

Intervention

Intervention code Lifestyle , Treatment: Other

This is a triple-blinded, 16-week, 1:1 parallel-group, randomised controlled trial. Women aged 18-75 years with low mood will be randomised to receive either A2 dairy products (A2 skim milk + A2 full fat cheddar cheese) or conventional dairy products (conventional skim milk + conventional full fat cheddar cheese). Participants will be provided with all study products, supplied by The a2 Milk Company, which are to replace usual amounts of dairy products consumed within the diet. Each day for 16 w ....
Read more

Comparison

Control group Active

Participants allocated to the control group will consume conventional dairy products (conventional skim milk + conventional full fat cheese) in amounts prescribed above. Control products will also be supplied by The a2 Milk Company. Control participants will complete the assessment schedule, as per the intervention group.

Outcomes

Outcome: Symptoms of psychological distress (depression, anxiety and stress) as measured by the Depression Anxiety Stress Scale-21 (DASS- 21) total score.
Timepoint: Baseline (week 0) and every two weeks after that (weeks 2, 4, 6, 8, 10, 12, 14, 16).

Data Dictionary: Not Available

Will individual participant data (IPD) for this trial be available?

yes

What data in particular will be shared?

All of the individual participant data collected during the trial, after de-identification.

When will data be available?

Immediately following publication. No end date.

Available to whom?

Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.

Available for what types of analyses?

Any purpose.

Source study information is derived from the Australian New Zealand Clinical Trials Registry (ANZCTR). For more information on the ANZCTR, please see anzctr.org.au